 Etoposide therapy testicular cancer past decades dramatic strides treatment metastatic testicular cancer early cisplatin vinblastine bleomycin PVB durable complete remissions CR treated patients early drug single-agent activity cisplatin-refractory patients preclinical data synergy cisplatin etoposide two-drug combination useful salvage therapy patients Further evaluation etoposide part initial therapy Southeastern Cancer Study Group SECSG PVB bleomycin cisplatin BEP untreated patients metastatic germ cell tumors BEP toxicity superior PBV patients advanced disease dose schedule etoposide patients useful avenues treatment High-dose etoposide carboplatin drug-refractory patients durable CR cohort treated patients part initial salvage therapy schedule dependency etoposide small cell lung cancer daily oral administration etoposide patients refractory previous etoposide therapy objective response rates summary etoposide integral part treatment regimen testis cancer incorporation innovative dose schedule combinations etoposide therapeutic index disease